[Prophylactic effect of enteral feeding preparations during the chemotherapy of oncology patients].
Altogether 124 patients were followed up for disseminated breast cancer (82) and hematosarcoma (42). The patients were divided into two groups: the main group was given 500 ml of 20% protein or low-lactose enteral feeding in addition to the hospital diet; the control group received only the hospital diet. Chemotherapy lasted 3 weeks. The patients on chemotherapy received enteral feeding every day throughout the entire treatment period. In the course of treatment, the patients were examined for blood characteristics, size of the tumor and affected lymph nodes, body weight, major metabolism, protein metabolism, vitamin metabolism, osmotic and peroxide resistance of red cells, and liver function. The research program covered more than 150 characteristics. The data obtained were processed by computer. It has been disclosed that inclusion of protein and low-lactose enteral feeding into the diet of cancer patients improves the alimentary status, decreases the leukopenia and thrombocytopenia incidence. It is advisable that specialized milk concentrates (enteral feeding) should be included into the diet of cancer patients as a necessary component of a complex of therapeutic measures used during chemotherapy.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004750:Enteral Nutrition; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005526:Food, Formulated; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Profilakticheskoe vliianie énpitov pri khimioterapii onkologicheskikh bol'nykh.